ESMO GI 2026: KRYSTAL-10 misses primary endpoints despite improved response rates in KRAS G12C-mutated metastatic colorectal cancer
The combination of adagrasib and cetuximab did not significantly improve progression-free survival (PFS) or overall…
The combination of adagrasib and cetuximab did not significantly improve progression-free survival (PFS) or overall…
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical…
Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral…
The chances of breast cancer recurring remain very low when patients are treated with radiotherapy…
Findings from the PRIMARY2 trial are presented at the European Association of Urology Congress in…
A new study led by UCLA Health Jonsson Comprehensive Cancer Centre investigators suggests that adding hormone therapy…
Results from a new phase 3 study found that for people with human epidermal growth…
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated…
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College…
Australian-led research has shown that a series of blood tests to detect ‘circulating tumour DNA’…